University of Louisville homepage
All experts
All experts

Peter Hedera

Professor Term

School of Medicine

Orcid identifier0000-0003-2699-4085
  • Professor Term
    School of Medicine

SPONSORED PROJECTS

  • Showing page 1 out of 1
Showing page 1, sponsored projects 1 to 17 of 17
GRANT
A randomized, placebo-controlled, double-blind Phase 3 study to evaluate the efficacy, safety and tolerability of votoplam in participants with Huntington\u2019s Disease
Novartis Pharmaceuticals Corporat_NOVART (SPN-000202)9 Feb 2026 - 31 Dec 2031
MORELEARN MORE
GRANT
CHTT227A12301: A randomized, placebo-controlled, double-blind Phase 3 study to evaluate the efficacy, safety and tolerability of votoplam in participants with Huntington\u2019s Disease
Novartis Pharmaceuticals Corporat_NOVART (SPN-000202)9 Feb 2026 - 8 Jan 2034
MORELEARN MORE
GRANT
AWD-00000135|Unversity of Louisville Huntington's Disease Center of Excellence
Huntingtons Disease Soc of America_HDSA1 Jan 2025
MORELEARN MORE
GRANT
240395|2024 Huntington's Disease Society of America Grant
Huntingtons Disease Soc of America_HDSA1 Jan 2024
MORELEARN MORE
GRANT
240628|A Multicenter Phase 2, Double-Blind Placebo-Controlled, Randomized, Parallel Group Study to Evaluate the Efficacy Safety, Tolerability and Pharmacokinetics of UCB0022 in Study with Advanced Parkinsons Disease.
UCB Biosciences_UCB1 Jan 2024
MORELEARN MORE
GRANT
220066|Interventional Post-Marketing, Multicentre, Randomized, Double-blind,Crossover Study to Evaluate the Clinical Safety and Efficacy of AbobotulinumtoxinA (Dysport) in Comparison with OnabotulinumtoxinA (Botox) when Treating Adults with Upper Limb Spasti
Parexel International Corporation_PIC1 Jan 2023
MORELEARN MORE
GRANT
230443|2023 HDSA Center of Excellence
Huntingtons Disease Soc of America_HDSA1 Jan 2023
MORELEARN MORE
GRANT
230132|A Multi-Center, Noninterventional Study Evaluating Variability, Reliability, and Compliance for the Parkinson's Disease Diary
BlueRock Therapeutics_BLUEROCK10 Oct 2022
MORELEARN MORE
GRANT
210885|2022 HDSA Center of Excellence
Huntingtons Disease Soc of America_HDSA1 Jan 2022
MORELEARN MORE
GRANT
220646|A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Dose Range Finding Clinical Trial to Evaluate the Tolerability, Safety, and Efficacy of PRAX-944 in the Treatment of Adults With Essential Tremor
Praxis Precision Medicines Inc_PPMI1 Jan 2022
MORELEARN MORE
GRANT
210810|OPTI-ON: Opicapone Treatment Initiation Open-Label Study
Neurocrine Biosciences Inc_NBI9 Sep 2021
MORELEARN MORE
GRANT
210885|2021 HDSA Center of Excellence
Huntingtons Disease Soc of America_HDSA1 Jan 2021
MORELEARN MORE
GRANT
220270|A Phase 2b, 12-Week, DB, PC, Randomized, Parallel-Group, MC Study of the Safety and Efficacy of CX-8998 in the Treatment of Adults with Moderate to Severe Essential Tremor
Jazz Pharmaceuticals Inc_JPI1 Jan 2021
MORELEARN MORE
GRANT
210296|PL101-HD301-A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Parallel Arm, Multicenter Study Evaluating the Efficacy and Safety of Pridopidine in Patients with Early State of Huntington Disease
Huntington Study Group_HSG1 Jan 2020
MORELEARN MORE
GRANT
Biological models of molecular pathogenesis if hereditary spastic paraplegia
National Institute of Neurological Disorders and Stroke30 Sep 2009 - 31 Aug 2012
People funded by this grant: HEDERA P
MORELEARN MORE
GRANT
Hereditary spastic paraplegia linked to chromosomes 8q
National Institute of Neurological Disorders and Stroke15 Dec 2001 - 30 Nov 2007
People funded by this grant: HEDERA P
MORELEARN MORE
GRANT
General Clinical Research Center
National Center for Advancing Translational Sciences1 Dec 1978 - 16 Sep 2007
People funded by this grant: DAVIS PB, HORWITZ RI, BERGER NA, CHERNIACK NS, SUDAK HS
MORELEARN MORE